ЭФФЕКТИВНОСТЬ СОВРЕМЕННОГО ИНГИБИТОРА АПФ ЗОФЕНОПРИЛА ПРИ ЛЕЧЕНИИ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ

1. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007 28: 14621-536.

2. Добровольский А.В., Сыркин А.Л. Место зофеноприла в терапии сердечно-сосудистых заболеваний. РМЖ. 2007; том 15, №2 0: 14721-476

3. Marzo A, Dal Bo L, Mazzucchelli P, et al. Pharmacokinetics and pharmacodynamics of zofenopril in healthy volunteers. Arzneimittelforschung. 1999 Dec; 49(12): 992-6.

4. Fyhrquist F. Clinical pharmacology of the ACE inhibitors. Drugs. 1986; 32 Suppl 5: 33 9.

5. Ambrosioni E. Defining the role of zofenopril in the management of hypertension and ischemic heart disorders. Am J Cardiovasc Drugs 2007; 7 (1): 172-4.

6. Lacourciйre Y, Provencher P. Comparative effects of zofenopril and hydrochlorothiazide on office and ambulatory blood pressures in mild to moderate essential hypertension. Br J Clin Pharmacol 1989 Mar; 27 (3): 3716-.

7. Farsang C. Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Pressure. 2007; 16 (Suppl 2): 19-24.

8. Nilsson P. Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. Blood Pressure. 2007; 16 (Suppl 2): 25-30.

9. Mallion JM. An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Pressure. 2007; 16 (Suppl 2): 13-18.

10. Malacco E, Piazza S, Omboni S. Zofenopril versus Lisinopril in the Treatment of Essential Hypertension in Elderly Patients: A Randomised, Double-Blind, Multicentre Study. Clin Drug Investig. 2005;25(3): 175-182.

11. Leonetti G., Rappelli A., Omboni S. A similar 24-h blood pressure control is obtained by zofenopril and candesartan in primary hypertensive patients. Blood Pressure. 2006; 15(Suppl 1): 18-26.

12. Westendorp B., Schoemaker R., von Gilst WH. Hydrochlorothiazide increases plasma or tissue angiotensin-converting enzyme-inhibitor drug levels in rats with myocardial infarction: differential effects on lisinopril and zofenopril. Eur J Pharmacol 2005 Dec 19; 527 (13-): 1419-.

13. Malacco E., Ombosini S. Antihypertensive efficacy of zofenopril plus hydrohlorthiazire fixed combination is superior to that of single components (abstract). Eur Heart J. 2005; 26 Suppl.1: 401.

14. Mak I T, Freedman AM, Dickens B F, et al. Protective effects of sulfhydryl-containing angiotensin converting enzyme inhibitors against free radical injuryin endothelial cells. Biochem Pharmacol 1990 Nov; 40 (9): 21697-5.

15. Evangelista S., Manzini S. Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril. The Journal of International Medical Research 2005; 33: 42 -54.

16. Pasini A F, Garbin U, Nava MC, et al. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am J Hypertens 2007 Apr; 20(4):443-50.

17. Napoli C, Sica V, de Nigris F, et al. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J. 2004 Jul; 148(1): e5.